Shares of Clearmind Medicine Inc. (CMND) surged over 70% on Monday morning after reporting encouraging clinical data.
The stock is currently trading at $1.23, up $0.51 or 70.02%, on the Nasdaq. It opened at $1.33 after closing the previous session at $0.72. The stock has traded between $0.59 and $52.40 over the past 52 weeks.
Clearmind said its CMND-100 drug candidate met the primary safety endpoint in a Phase I/IIa trial for Alcohol Use Disorder (AUD).
The treatment showed strong tolerability with no serious adverse events, supporting further development.
The results boost confidence in its non-hallucinogenic psychedelic-based therapy pipeline.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.